JB Chemicals & Pharmaceuticals is planning to acquire brands for the India market from Sanzyme (Sanzyme), a leading player in the probiotics and reproductive health segment in the country. The transaction is valued at Rs 628 crore and is expected to be completed in the next two weeks subject to customary closing formalities.
Sanzyme, ranked amongst the top five probiotics players in the country, is engaged in the manufacture, distribution and marketing of specialty probiotics formulations, infertility management products and nutraceuticals products. Following the acquisition, these products will derive significant visibility by leveraging company’s distribution network across the country. The acquisition will mark company’s entry into the fast-growing probiotics, therapeutic nutraceuticals and reproductive health market with attractive set of brands.
JB Chemicals & Pharmaceuticals is engaged in manufacturing of pharmaceutical specialties in various dosage forms, herbal remedies, diagnostics, generic drugs, active pharmaceutical ingredients (APIs).
